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Abstract: Objectives:  This systematic review (PROSPERO CRD42019115918) compared the
evidence behind anticholinergic burden measures and their ability to predict changes in
older people's physical function and quality of life.
Design:  Eligible cohort or case-control studies were identified systematically using
comprehensive search terms and a validated search filter for prognostic studies.
Medline (OVID), EMBASE (OVID), CINAHL (EMBSCO) and PsycINFO (OVID)
databases were searched. Risk of bias, using Quality in Prognosis Studies tool, and
quality of evidence, using GRADE, were assessed.
Setting and Participants:  People aged 65 years and older from any clinical setting.
Measures:  Any anticholinergic burden measures were accepted (including the
anticholinergic domain of the Drug Burden Index). Any global/ multi-dimensional
measure for physical function and/ or quality of life was accepted for outcome.
Results:  Thirteen studies reporting associations between anticholinergic burden and
physical function (n=10) or quality of life (n=4) were included. Exposure measures
included; Anticholinergic Cognitive Burden Scale, Anticholinergic Drug Scale,
Anticholinergic Risk Scale, Clinician Rated Anticholinergic Score and the
anticholinergic domain of the Drug Burden Index. All studies were rated moderate risk
of bias in ≥2 QUIPS categories with five rated high risk in ≥ 1 categories. Seven of ten
studies (5,251 of 7,569 participants) reported significant decline in physical function
with increased burden. All four studies (2,635 participants) reporting quality of life
demonstrated similar association with increased burden. High risk of biases and
inadequate data reporting restricted analysis. There was no evidence to support one
measure being superior to another.
Conclusions and Implications:
The evidence supports association between increased anticholinergic burden and
future impairments in physical function and quality of life. No conclusion can be made
regarding which ACB measure has the best prognostic value. Well-designed
longitudinal studies are required to address this. Clinicians should be aware of patient’s
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anticholinergic burden and consider alternative medications where appropriate.
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Title: Anticholinergic Burden Measures Predict Older People’s Physical Function and Quality 1 
of Life: A Systematic Review 2 
Running Title: Anticholinergic Burden and Older People’s Function and Quality of Life 3 
Abstract: 4 
Objectives: This systematic review (PROSPERO CRD42019115918) compared the evidence 5 
behind anticholinergic burden measures and their ability to predict changes in older people’s 6 
physical function and quality of life. 7 
 8 
Design: Eligible cohort or case-control studies were identified systematically using 9 
comprehensive search terms and a validated search filter for prognostic studies. Medline 10 
(OVID), EMBASE (OVID), CINAHL (EMBSCO) and PsycINFO (OVID) databases were searched. 11 
Risk of bias, using Quality in Prognosis Studies tool, and quality of evidence, using GRADE, 12 
were assessed. 13 
 14 
Setting and Participants: People aged 65 years and older from any clinical setting.  15 
 16 
Measures: Any anticholinergic burden measures were accepted (including the anticholinergic 17 
domain of the Drug Burden Index). Any global/ multi-dimensional measure for physical 18 
function and/ or quality of life was accepted for outcome. 19 
 20 
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Results: Thirteen studies reporting associations between anticholinergic burden and physical 21 
function (n=10) or quality of life (n=4) were included. Exposure measures included; 22 
Anticholinergic Cognitive Burden Scale, Anticholinergic Drug Scale, Anticholinergic Risk Scale, 23 
Clinician Rated Anticholinergic Score and the anticholinergic domain of the Drug Burden 24 
Index. All studies were rated moderate risk of bias in ≥2 QUIPS categories with five rated high 25 
risk in ≥ 1 categories. Seven of ten studies (5,251 of 7,569 participants) reported significant 26 
decline in physical function with increased burden. All four studies (2,635 participants) 27 
reporting quality of life demonstrated similar association with increased burden. High risk of 28 
biases and inadequate data reporting restricted analysis. There was no evidence to support 29 
one measure being superior to another. 30 
 31 
Conclusions and Implications:  32 
The evidence supports association between increased anticholinergic burden and future 33 
impairments in physical function and quality of life. No conclusion can be made regarding 34 
which ACB measure has the best prognostic value. Well-designed longitudinal studies are 35 
required to address this. Clinicians should be aware of patient’s anticholinergic burden and 36 
consider alternative medications where appropriate.  37 
 38 




Physical function and quality of life are two important health outcomes for older people.1 41 
Physical function focuses upon an individual’s activities and participation, particularly in 42 
relation to what would be considered normal general daily tasks, self-care activities, and 43 
participation in community and social interactions.2 Quality of life overlaps this, defined as “a 44 
broad ranging concept affected in a complex way by the person's physical health, 45 
psychological state, personal beliefs, social relationships and their relationship to salient 46 
features of their environment”. 3 Quality of life is concerned more with the impact of activity 47 
and participation limitations upon well-being.4 Both outcomes are considered key research 48 
priorities by both older people and health professionals.1 49 
 50 
Understanding what influences these outcomes is important; factors which are modifiable 51 
can be targeted to improve older people’s physical function and quality of life. One potentially 52 
important factor is anticholinergic burden (ACB)5-6 the accumulation of anticholinergic effects 53 
from one or more anticholinergic medications.7-8 Medications with anticholinergic properties 54 
are prescribed for a range of common problems in older age, including urinary incontinence, 55 
depression and gastrointestinal complaints.8-9 Side-effects include confusion, constipation, 56 
delirium, dizziness, drowsiness and dry mouth.8-9 Studies estimate up to 50% of community 57 
dwelling older adults use one or more anticholinergic medications.10-11 However, in addition 58 
to being the greatest consumers of anticholinergic medications, older people are more 59 
susceptible to side effects and adverse outcomes.8 To date, while a number of  reviews in this 60 
area have included older people, few reviews have specifically restricted inclusion and 61 
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analysis to older people. Therefore there is an urgent need to understand anticholinergic use 62 
and its consequences within the older adult population. 63 
 64 
Several factors presently limit advancing knowledge in this area, not least study design and 65 
choice of ACB measure. Our previous (unpublished) research identified fourteen ACB 66 
measures reported in the literature. The variation in ACB measures makes interpretation 67 
challenging; the ACB measures differ substantially.12-13 The number of medications assessed 68 
in each scale varies from 27 in the Anticholinergic Burden Classification, to 117 in the 69 
Anticholinergic Drug Scale.13 The potency score for individual medications also varies between 70 
scales.13 For example, Nortriptyline is rated as having high anticholinergic activity by Boustani 71 
et al., (2008) in the Anticholinergic Cognitive Burden Scale14 but moderate by Rudolph et al., 72 
(2008) in the Anticholinergic Risk Scale15. As yet no evidence provides clear rationale to 73 
support use of one measure above another.  Additionally, many reviews have included cross-74 
sectional study designs, restricting our understanding of the temporal relationship between 75 
ACB and future outcomes. There is a need to explore the ability of individual ACB measures 76 
to predict these outcomes and identify if one ACB measure performs better than another. 77 
Understanding the prognostic utility of ACB measures will enhance future outcome reporting 78 
for trials seeking to reduce ACB.  79 
 80 
This systematic review aims to: 81 
 describe the association of individual ACB measures with physical function and quality of 82 
life, and 83 
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 compare the prognostic utility of ACB measures.  84 
 85 
Methods 86 
This PROSPERO registered systematic review (CRD42019115918, available: 87 
http://www.crd.york.ac.uk/PROSPERO ) was conducted using the Cochrane Prognostic 88 
Review Group Framework for Prognostic Reviews 89 
(https://methods.cochrane.org/prognosis/our-publications)16 and reported in accordance 90 
with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (see 91 
supplementary file 1 for PRISMA checklist).  92 
 93 
Literature search strategy 94 
The search strategy was developed following extensive scoping searches to identify 95 
appropriate MeSH and other controlled vocabulary for ACB and ACB measures. We employed 96 
a validated search filter for the identification of prognostic studies.17 The strategy was 97 
modified to suit each database searched (MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCO) 98 
and PsycINFO (Ovid)). Searches were from 1st January 2006 to 4th March 2020.  The 2006 99 
inception was chosen as the time when ACB was first conceptualised and studied. The full 100 
strategy is reported in our supplementary file 1.  101 
 102 
Inclusion criteria 103 
The following criteria were applied to identify appropriate studies: 104 
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 Report a prospective or retrospective observational study (longitudinal cohort or case-105 
control) 106 
 Involve adults aged ≥65 years (or mean age ≥ 65 years) 107 
 Assess ACB exposure using any ACB measure (to include anticholinergic (Ach) domain of 108 
the Drug Burden Index (DBI)) 109 
 Any length of follow-up period 110 
 Report any global/ multi-dimensional measure of physical function and/ or quality of life 111 
as an outcome 112 
 113 
Exclusion criteria 114 
The following exclusion criteria were applied: 115 
 Studies restricted to measuring classes of or specific anticholinergic medications (e.g. 116 
psychotropics) 117 
 Measure of medications not specifically directed at anticholinergic drugs (e.g. Beers 118 
criteria) 119 
 120 
Study selection process  121 
Searches were conducted on the 16th November 2018, then updated on 4th March 2020 and 122 
identified studies transferred to Covidence systematic review software ©2019 (Veritas Health 123 
Innovation Ltd., www.covidence.org). After duplicates were removed, 13,394 studies 124 
remained. These were then screened by title and abstract by two independent reviewers 125 
(shared between CS, KY, MK). Both primary reviewers had to agree upon exclusion and, where 126 
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this was not the case, a third independent reviewer made the final decision (TQ). The full text 127 
of remaining studies (n=124) were screened by two independent reviewers (shared between 128 
CS, KY, MK). Again, a third independent reviewer resolved any disagreements (TQ). Exclusion 129 
reasons are reported in the identified PRISMA flow chart (Supplementary file). Reference lists 130 
of included studies were searched, and citations via PubMed reviewed, to check for studies 131 
our search had omitted. Reference lists and citations of recent seminal articles13,18 were also 132 
searched. No additional studies for inclusion were identified. Thirteen articles remained 133 
which reported physical function or quality of life as an outcome. 134 
 135 
 136 
Data collection and extraction 137 
A data extraction template was developed in accordance with guidance by the Cochrane 138 
Prognostic Review Group framework (https://methods.cochrane.org/prognosis/our-139 
publications).16 This included study characteristics (e.g. year of publication, country, study 140 
setting), measures assessed, timing and methods of assessments, statistical plan, 141 
confounders/ adjustments and results. Two reviewers (shared between CS, KY, MK) 142 
independently extracted data and a third reviewer arbitrated any disagreements (TQ). Data 143 
were then transferred to a Microsoft Excel 2016 (https://products.office.com/en-gb/excel) 144 
sheet and imported to Comprehensive Meta-Analysis v3.3.070 (https://www.meta-145 
analysis.com/) for analysis. 146 
Risk of bias 147 
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Risk of bias for each included study was assessed using the Quality in Prognosis Studies tool, 148 
developed by the Cochrane Prognosis Methods Group (QUIPS, available: 149 
https://methods.cochrane.org/sites/methods.cochrane.org.prognosis/files/public/uploads/150 
QUIPS%20tool.pdf).19 Risk of bias is assessed across six domains: study participation, attrition, 151 
prognostic measurement, outcome measurement, study confounding and statistical analysis. 152 
As recommended, we took the QUIPS anchoring statement and modified the wording to suit 153 
our review question. We agreed to accept any baseline measure of ACB and for statistical 154 
analysis we agreed within the research team a minimum level of adjustment (set of 155 
confounders) that would constitute high quality (discussed further below). Assessments were 156 
conducted by those who completed data extraction (CS, KY, MK) and any disagreements 157 
arbitrated by a third reviewer (TQ). Publication bias was planned to be assessed by way of 158 
funnel plot. 159 
 160 
Analysis 161 
All included studies underwent narrative analysis following the guidance provided by the 162 
European Social Research Council.20 Findings were assessed qualitatively considering clinical 163 
heterogeneity and the risk of biases. Patterns of associations across the studies were also 164 
explored and described. Association data extracted included odds ratios, risk ratios, their 165 
respective confidence intervals, β values, standard error and p values, where reported. 166 
Baseline and follow-up scores for ACB and relevant outcome were recorded if reported. 167 
Pooled analysis was planned with summary statistics where possible for both adjusted and 168 
unadjusted data.  169 
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Which factors and what constitutes minimum adjustment was determined by consensus, 170 
using a Delphi approach involving the senior authors (CS, RLS, YKL, PKM). It was agreed after 171 
one round that minimum adjustment would be age and sex and ≥1 co-morbidities (or a global 172 
measure of the number of co-morbidities). Where possible forest plots and meta-analyses 173 
using random effects modelling techniques were planned to graphically and statistically 174 
demonstrate the body of evidence. Results were analysed according to our hierarchy of 175 
research questions:  176 
 Prognostic utility of individual ACB measures for each outcome of interest (all measures 177 
for either physical function or quality of life combined) 178 
 Comparison of prognostic utilities of ACB measures for each outcome of interest (all 179 
measures for either physical function or quality of life combined) 180 
 181 
Quality assessment 182 
The GRADE assessment tool was used to determine the quality of the body of evidence for 183 
each scale and outcome. The GRADE approach assesses the evidence across all studies 184 
analysed for a given outcome, rather than assessing the evidence from each study 185 
individually.21 The GRADE framework allows the quality of the evidence to be judged across 186 
criteria known to limit the quality of evidence.21 Guidance for applying GRADE to prognostic 187 
studies was taken from Huguet et al. (2013).22 Quality was assessed across seven criteria; 188 
study limitations, inconsistency, indirectness, imprecision, publication bias, effect size and 189 






Of the 13 studies23-35, ten reported associations between ACB and physical function 23,24,26,27, 194 
29-34 and four reported associations with quality of life 23,25,28,35. One study 23 is reported twice 195 
as it reports both outcomes.  Five measures for ACB exposure were included; Anticholinergic 196 
Cognitive Burden Scale, Anticholinergic Drug Scale (modified- Clinician Rated Anticholinergic 197 
Score), Anticholinergic Risk Scale, Clinician Rated Anticholinergic Score, and the 198 
anticholinergic domain of the Drug Burden Index. Each scale was developed within the United 199 
States of America. The Anticholinergic Cognitive Burden Score assesses 88 medications 200 
considered by expert opinion to have anticholinergic properties which have significant impact 201 
upon cognition. 24 The Anticholinergic Drug Scale assesses 117 medications which are scored 202 
based on each medications serum anticholinergic activity as published in the existing 203 
literature. 13,35 The Anticholinergic Drug Scale was originally known as the modified Clinician 204 
Rated Anticholinergic Score. 13 The Anticholinergic Risk Scale assesses 49 medications 205 
considered to have anticholinergic properties which have significant impact on both cognitive 206 
and physical function. 24 The Clinician Rated Anticholinergic Score assess 60 medications, 207 
identified from several ACB scales, considered strongly implicated in the development of 208 
delirium.  13,26  The anticholinergic domain of the Drug Burden Index is somewhat different 209 
from other ACB measures in that it considers dose and duration of use of individual 210 
anticholinergic medications. 28 It was also developed based upon existing literature and expert 211 
opinion. 28 212 
Physical function  213 
Descriptive details for each study are presented in table 1. In total 7,569 older people 214 
participated across the ten studies, with mean (+/-SD) ages ranging from 71.9 (12.0) years 23 215 
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to 86.1 (6.8) years.29 Three studies were conducted in Italy 24,32,34, three in the USA 26,29,31 and 216 
one each from Australia 23, Israel 27, Spain 33 and the U.K. 30   217 
 218 
Table 2 Characteristics of studies reporting association between ACB and physical function 219 
(n=10) and quality of life (n=4) 220 
 221 
Risk of bias for each study (n=10) is presented in Figure 1. Of the ten studies, four papers were 222 
considered high risk of bias ≥1 QUIPS categories.23,29,31,34 High risk of bias arose most 223 
commonly from issues around participation, including poor descriptions of sample group23, 224 
inadequate description of those excluded31 or little information regarding participation rate.29 225 
Moderate risks of bias were common throughout all studies; attrition (the number, reasons 226 
for or exploration of outcome factors in those lost) was rarely addressed. A funnel plot for 227 
assessing publication bias was not possible due to variation in statistical effect sizes presented 228 
and too few studies.  229 
 230 
Fig. 1. QUIPS Risk of bias assessment of studies reporting association between ACB and 231 
physical function (n=10) and quality of life (n=4) 232 
 233 
Anticholinergic Cognitive Burden Scale (ACBS) and physical function 234 
Six studies, with sample sizes ranging from n=9929 to n=142931 explored the relationship 235 
between baseline ACB and future physical function using the ACBS (See table 2). Three studies 236 
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reported significant associations between increased ACB and impaired physical function24,29,31 237 
with little difference between un-adjusted and adjusted results. Brombo 2018 24 reported the 238 
strongest association between increased ACBS score and a decline in Activities of Daily Living 239 
scores (2.77, 95% CI 1.39,5.54).  Inconsistencies between studies regarding statistical analysis 240 
and data presented limited further analysis. For example, as shown in table 2 the six studies 241 
utilised four different physical function outcome measures and varied in comparison groups 242 
(e.g. ACBS=0 v ACBS ≥1 or ACBS≤1 v. ACBS ≥2).  243 
 244 
Table 2 Summary of results for studies reporting impact of ACB upon physical function (n=10) 245 
 246 
Anticholinergic Risk Scale (ARS) and physical function 247 
Four studies with sample sizes ranging from n=10530 to n=149032 explored relationships 248 
between ACB and physical function using the ARS (table 2). Studies varied in statistical analysis 249 
and findings; two of four studies reported significant association between baseline ARS and 250 
future functional decline.30,32 Notably, Brombo 2018 24, in contrast to their findings using the 251 
ACBS,  failed to find a positive association between function and ACB using the ARS measure 252 
(OR 1.49, 95% CI 0.60, 3.70). 253 
 254 
Clinician Rated Anticholinergic Score (CRAS) & modified Clinician Rated Anticholinergic 255 
Score (mCRAS) and physical function 256 
Two studies explored relationships between ACB and physical function using the CRAS or 257 
mCRAS.23,26 Sample sizes ranged from n=461 23 to n=544 26. Agar (2009)23 reported an OR 0.85 258 
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(95% CI 0.81, 0.90) between the baseline CRAS of older palliative care patients and a decrease 259 
in Australian-modified Karnofsky Performance Status (AKPS) category; those with higher ACB 260 
were less likely to be classed as independent at follow-up. Han (2008)26 reported an effect 261 
estimate of 0.10 (95% CI 0.04, 0.17) suggesting for every unit increase in mCRAS score there 262 
is a 10% reduction in IADL (i.e. lower independence).  263 
 264 
Comparison of prognostic ability of ACB measures to predict future physical function 265 
Only two studies directly compared >1 ACB measures in the same population; Brombo 266 
(2018)24 and Pasina (2013)34 both compared the ACBS and ARS abilities to predict future 267 
physical function.  Brombo (2018)24 reported associations with the ACBS but not ARS, while 268 
Pasina (2013)34 failed to find a significant relationship with either the ACBS or ARS. 269 
 270 
Quality of Life outcome studies 271 
In total 2,635 older people participated across the four studies, with mean (SD) ages ranging 272 
from 71.0 (12.0) years23 to 78.6 (6.7) years28. Two studies were conducted in the U.S.A.28,35 273 
and one each from Australia23 and Canada.25 Further details of each study are presented in 274 
table 1.  275 
 276 
Risk of bias for each study (n=4) is presented in Fig. 1. Of the four studies, two papers were 277 
considered high risk of bias in ≥1 QUIPS categories.23,35High bias risks arose from a lack of 278 
reporting of, or adjustment for, confounders and unclear analysis plans.23,35 Moderate risks 279 
of bias were common throughout; Participation rates were rarely reported, the number, 280 
14 
 
reasons for or exploration of those lost to follow up was rarely addressed, along with non-281 
reporting of missing data. A funnel plot for assessing publication bias was not possible due to 282 
variation in statistical effect sizes presented and too few studies.  283 
 284 
ACBS and quality of life 285 
Two studies, with sample sizes ranging from n=42628 to n=179325 explored the relationship 286 
between baseline ACB and quality of life using the ACBS. Table 3 summarises results. Cossette 287 
(2017) identified a significant association between baseline ACB and the physical domain of 288 
the SF36 (β -0.50 (95% CI -0.31, -0.68) p<.001)) but not the mental domain (β 0.19 (95% CI 289 
0.01,0.37) p=ns).25 Conversely, using the EQ5D, Ie (2017) did not identify any association with 290 
ACBS score over 12 months (β 0.006 (95% CI -0.01 to 0.02) p=ns)).28 Cossette (2017) do not 291 
present results combining the domains of the SF36 making it difficult to compare the two sets 292 
of results.25 293 
 294 
Table 3 Summary of results for included studies reporting impact of ACB upon quality of life 295 
(n=4) 296 
 297 
Anticholinergic Drug Scale (ADS) and quality of life 298 
Two studies with sample sizes ranging from n=11235 to n=179325 explored relationships 299 
between ACB and physical function using the ADS (shown in table 3). Both studies 300 
demonstrated moderate significant associations between increased ACB measured by the 301 
ADS and the physical domain of the SF36 (β - 0.30 (95% CI -0.10, -.51) p<.01)25 and SF12 (est. 302 
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-7.48 (95% CI -12.57, -2.39) p<.01)35 respectively. Neither study detected association between 303 
the ADS and the mental domains of the SF36 (β –0.07 (95% CI –0.28, 0.13) p=ns) or SF12 304 
(Mean between group difference in SF12 scores –2.27 (95% CI -7.81, 3.27) p=0.43)25,35.  305 
 306 
ARS and quality of life 307 
Only one study explored relationships between ACB and quality of life using the ARS.25 Results 308 
are detailed in table 3, but again a significant association with the physical, but not the mental, 309 
domains of the SF36 were identified.  310 
 311 
Drug Burden Index- Anticholinergic sub scale (DBI-Ach) and quality of life 312 
Only one study explored the relationship between DBI-ACh and quality of life28which 313 
demonstrated a small but significant relationship with reduced quality of life measured by the 314 
EQ5D (table 3).28  315 
 316 
Modified Clinician Rated Anticholinergic Score (mCRAS) and quality of life 317 
Only one study explored the relationship between mCRAS and quality of life23 which 318 
demonstrated significant association with the McGill Quality of Life score (table 3). Those with 319 
higher ACB scores reported poorer quality of life at follow-up.23   320 
 321 
Comparison of prognostic ability of ACB measures to predict future quality of life 322 
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Only two studies directly compared different ACB measures in the same population sample; 323 
Cossette (2017)25 compared three measures (ACBS, ADS ARS), while Ie (2016)28 compared the 324 
ACBS and DBI-ACH, to predict quality of life. The ACBS demonstrated the strongest 325 
associations in comparison to the ADS and ARS.25 Ie (2016) demonstrated a stronger 326 
relationship using the DBI-ACH than the ACBS, however associations were very small (β -327 
0.095, p<.05). 28 328 
 329 
GRADE Assessment 330 
All GRADE assessments conducted for each ACB scale and outcome combination resulted in 331 
an assessment of ‘Very Low’, meaning that we have little confidence in the results and further 332 
studies will likely change the results. Quality was commonly downgraded due to serious 333 
concerns regarding study biases, inconsistency in results, indirectness, potential for 334 
publication bias and small effect sizes (see supplementary file 1 for detailed GRADE 335 
assessments).  336 
 337 
Discussion 338 
This systematic review included 13 studies reporting the prognostic value of one or more ACB 339 
measures in relation to physical function or quality of life in older people. Seven out of ten 340 
studies reported a significant association between increased ACB and future impaired 341 
physical function, with the remaining studies showing a non-significant trend towards this. 342 
However, statistical and clinical heterogeneity prevents meta-analysis and our ability to 343 
recommend one measure above another. In relation to quality of life, four studies reported 344 
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the longitudinal relationships between ACB and quality of life amongst older people. Each 345 
study reported at least one significant association between ACB and quality of life, but again 346 
limited evidence prevents recommending one measure above another. At present, the 347 
evidence behind the ability of individual ACB measures to predict future physical function and 348 
quality of life is poor and does not permit informed decisions regarding which measure is best 349 
to assess ACB.  We conclude that, in relation to older people, ACB shows a general trend 350 
towards impaired physical function and reduced quality of life but the question as to which 351 
ACB measure performs best remains unanswered. 352 
 353 
In the review by Fox et al., (2014)5 studies which failed to associate ACB and physical function 354 
often focused upon single domain aspects of function e.g. walking ability. Our study excluded 355 
such outcomes to focus upon global measures that are more comparable between 356 
populations. However, it has been suggested that specific domains of physical function such 357 
as gait may play important mediating roles between ACB and other adverse outcomes such 358 
as falls.36  Research focusing upon the temporal relationship between ACB and global physical 359 
function, specific physical abilities and how these relate to other outcomes are required to 360 
advance our understanding of the complexities of this relationship.  361 
 362 
Our findings support a general trend for increased ACB being associated with a reduction in 363 
quality of life; however, the evidence is limited by few studies and low study quality. The 364 
divergence in results between domains of quality of life, demonstrating greatest associations 365 
with the physical domain of quality of life than the mental domain, is not unique to ACB. 366 
Similar results were recently published in relation to associations between multi-morbidity 367 
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and quality of life where strong associations with physical, but not mental domains were also 368 
found.37 Exploration of older peoples perspectives towards ACB and its impact upon quality 369 
of life is necessary to further understand what aspects, if any, ACB is perceived to impact 370 
upon, which may help explain this finding. 371 
 372 
The number of, and variations between ACB measures, has been documented previously.13,38 373 
Many were developed to target specific adverse outcomes, most commonly cognitive 374 
impairment and dementia.13,38 These may nevertheless be associated with the outcomes 375 
assessed in this review because cognitive impairment is associated with poorer physical 376 
function39 and quality of life,40 and because anticholinergics are well known to have many 377 
other adverse effects beyond cognitive impairment.  Reliance upon expert rated 378 
anticholinergic potency is troublesome due to divergent views amongst clinicians. 13,38 379 
Conversely attempts to rate anticholinergic potency objectively is not without its limitations, 380 
not least discordance between measurable biological markers and symptoms of 381 
anticholinergic properties. 13,38 Despite our intentions this present review cannot answer the 382 
question as to which ACB measure may be most suitable for predicting specific outcomes. The 383 
small number of studies, diverse range of outcome measures, and substantial differences in 384 
study characteristics means determining one ACB measure as being a better predictor of 385 
future physical function or quality of life is not possible. To improve prognostic research 386 
future research should be prospective longitudinal or case-control in design and sufficiently 387 
large, with sample size calculations appropriate for the outcome of interest and adjust for 388 




The strengths of this systematic review include its novelty in both focusing upon comparing 391 
ACB measures and being restricted to older people. Other strengths include its 392 
comprehensive search strategy using a validated search filter to identify relevant studies, 393 
reference list checks of all included studies and any seminal studies not included to ensure no 394 
eligible studies were omitted, and our decision to focus on longitudinal and case-control 395 
studies more suited to understanding adverse outcomes. However, this review also has some 396 
limitations. We did not include grey literature; while this can help avoid contaminating results 397 
with low quality non-peer reviewed evidence, we cannot say with certainty that its exclusion 398 
did not result in the omission of insightful and relevant papers. Finally, the small number of 399 
studies identified meant it was not possible to adequately assess for publication bias so we 400 
have to assume there is a possibility of this.   401 
 402 
Conclusions and Implications 403 
This systematic review identified 13 studies reporting the prognostic value of one or more 404 
ACB measures in relation to physical function or quality of life. The majority of studies show 405 
at least a general trend towards impaired function and reduced quality of life associated with 406 
increased ACB. At present the evidence behind individual ACB measures’ ability to predict 407 
physical function and quality of life amongst older adults is poor and does not permit 408 
informed decisions regarding which is the best measure to use.  Well-designed longitudinal 409 
studies are required to address this. However, the general consistency in our findings, 410 
alongside the wider body of evidence, suggests clinicians should continue to be aware of 411 
individual patients’ anticholinergic burden and consider alternatives to anticholinergic 412 
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Table 1 Characteristics of studies reporting association between ACB and physical function (n=10) and quality of life (n=4) 
Study 
(Design) 













Agar 200923 Prospective 461* 71.9 
(12.0) 
232 (50.0) Australia Palliative care Death (mean 
107 days) 
CRAS AKPS MQoL 
Brombo 201824 
 
Retrospective 1123 81.0 (7.4) 494 (44.0) Italy Acute care 
(hospital) 
1 year ARS & 
ACBS 
ADL (Katz) - 
Cossette 201725 
 
Prospective 1793 74.4 (4.2) 853 (48) Canada Community 36 months ACBS, 
ADS & 
ARS 
-  SF36 
Han 200826 
 
Prospective 544 74.4 (5.2) 544 
(100.0) 
USA Primary care 
clinic  




Retrospective 869 83.4 (6.9) 
† 





ACBS FIM - 
Ie 201728 
 
Retrospective 426 78.6 
(6.72) 
48 (11.3) USA Care homes & 
Community 





































ARS BI - 
Koyama 201431 
 
Prospective 1429 83.0 (3.1) 0 (0.0) USA Community 5 years ACBS IADL (NS) - 
Landi 201432 
 
Prospective 1490 83.6 
(65.1-
106.4) ‡ 






Retrospective 126 80.0 (6.7) 28 (27.8) Spain Geriatric clinic 
(hospital) 
1 year ACBS BI - 
Pasina 201334 
 
Retrospective 1323 79.9 (7.3) 
† 















48 (42.9) USA Community 24 months ADS - SF-12 
ACB: Anticholinergic Burden, ACBS: Anticholinergic Cognitive Burden Scale, ADL: Activities of Daily Living, ADS: Anticholinergic Drug Scale, AKPS: Australian-
modified Karnofsky Performance Status, ARS: Anticholinergic Risk Scale, BI: Barthel Index, CRAS: Clinician Rated Anticholinergic Score, DBI-Ach: Drug Burden 
26 
 
Index Anticholinergic sub-scale, EQ-5D: EuroQol 5D, FIM: Functional Independence Measure, IADL: Instrumental Activities of Daily Living, mCRAS: modified 
Clinician Rated Anticholinergic Score, MDS-HC: Minimum Data Set for Home Care, MQoL: MacGill Quality of Life Score, NR: Not Reported, NS: Not Specified, 
OARS: Older American Resources and Services, QoL: Quality of Life, SF-12: Short Form Health Survey 12, SF-36: Short Form Health Survey 36. 
 
*461 participants recruited but Quality of Life analysis conducted with 304 participants who died during study follow-up; †Mean age for ACB users within 
sample; ‡ Median and IQR presented instead of mean (SD)  
27 
 
Fig. 1. QUIPS Risk of bias assessment of studies reporting association between ACB and 
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Table 2 Summary of results for studies exploring prognostic relationships between ACB scale and physical function (n=10) 
Scale/ Outcome  Study ACB (Baseline) Physical 
Function 
(Baseline) 












Any ADL: 542 
(48.3%) 
Multivariable logistic regression 
 OR 95% CI (ACBS ≥1 versus ACBS=0) 
2.38 (1.37,4.13) 
p=.002  
 2.77 (1.39, 5.54) 
p=.004* 
   ACBS≥2: 348 
(31.0%) 
    




ACBS Mild: 81 
(81.8%) 
NR Multiple linear regression 
 β (SE) 
NR Mild:  -3.41 
(2.14) p= NS † 
   ACBS Mod/Sev: 
25 (25.2%) 
   Mod/sev: 5.76 
(1.99) p=<0.05  
  Lopez-Matons 
201833 
ACBS≥1: 26.4% BI (Mean, SD): 
88.9 (18.5) 
Difference in the BI scores between 
exposed and unexposed patients 
Mean (SD) (95% CI) 
-4.3 (3.3)  
(-10.8, -2.2)   
−4.0 (4.5)  
(−12.9, 4.9) ‡ 
  Pasina 201334 ACBS≥1: 724 
(58.8%) 
NR Correlation                                  
Pearson Coefficient 
0.004 p = 0.91 NR 




ACB ≤1: 666 
(76.6%) 
60.5 (17.8) Multiple linear regression 
β (SE) 
NR - 0.03 (0.85) 
p=0.02 § 
   ACB≥2: 203 
(23.4%) 
56.3 (18.7)    
29 
 
Scale/ Outcome  Study ACB (Baseline) Physical 
Function 
(Baseline) 









(SD): 1.6 (1.9) 
NR Multiple logistic regression  
OR (95 % CI) 
1.11 (1.04, 1.18) 
p=NR 
 1.11 (1.04, 1.19) 
|| p=NR  
ARS 
(Range 0-3) 






ADL any: 542 
(48.3%) 
Multivariable logistic regression  
OR 95% CI  
2.43 (1.26,4.68) 
p=.008  
1.49 (0.60, 3.70) 
p=.38 * 
  Landi 201432 ARS≥1: 721 
(48.4%) 
ADL Mean (SD): 
15.4 (10.3) 
Multivariable logistic regression 
OR (95% CI) 
NR 1.13 (1.03, 1.23) 
p=.01 ** 









Poisson regression  
IRR (95% CI) 
NR 0.97 (0.95, 0.99) 
p=0.008 †† 




-0.06 p = 0.15 NR 
CRAS/ mCRAS 
(Range 0-3) 
AKPS             
(Range 0-100) 
 Agar 200923 NR AKPS (Mean, 
SD): 61.0 (13.8) 
Logistic regression  
OR (95% CI) 
NR  0.85 (0.81, 0.90) 
p= NR ‡‡ 
IADL              
(Range 0-8) 
 Han 200826 CRAS Mean 
(SD): 1.3 (1.5) 
IADL Mean (SD): 
6.5 (1.07) 
Mixed effects linear regression  
Effect Estimate (95% CI) 
0.16 (0.11, 0.25) 
p=.001  
0.10 (0.04, 0.17) 
p= 0.001. §§ 
ACB: Anticholinergic Burden ACBS: Anticholinergic Cognitive Burden Scale, ADL: Activities of Daily Living, AKPS: Australian-modified Karnofsky Performance 
Status, ARS: Anticholinergic Risk Scale, BI: Barthel Index, CRAS: Clinician Rated Anticholinergic Score, FIM: Functional Independence Measure, IADL: 





* Adjusted for age, sex, education, smoking, mini-mental state examination score, ACBS score at first follow-up, hypertension, coronary heart disease, 
renal failure, anaemia, infectious diseases. 
† Adjusted for gender, ethnicity, Charlson comorbidity index, clinical dementia rating, age, Apolipoprotein E status, education, previous weekly function 
performance. 
‡ Adjusted for age, sex, body mass index, smoking, high blood pressure, diabetes, dyslipidaemia, heart disease, stroke, dementia. 
§ Adjusted for age, sex, time from surgery to rehabilitation, admission albumin level, education, presence of caregiver, residency, mini-mental state 
examination score, admission FIM, ischemic heart disease, congestive heart failure, diabetes, hypertension, cardiovascular disease, depression, 
Parkinson’s, chronic obstructive pulmonary disease.  
|| Adjusted for age, race, years of education, smoking, physical activity, Charlson comorbidity index.  
** Adjusted for schizophrenia, depression, cognitive performance scale score, age, sex, cumulative index rating scale, activities of daily living (baseline) 
†† Adjusted for age, sex, Charlson comorbidity index, abbreviated mental test, total of other medications, Barthel index at admission 
‡‡ Adjusted for time before death 
§§ Adjusted for age, race, education, living arrangement, follow-up year, baseline value of the outcome, activities of daily living, centre-epidemiological 





Table 3 Summary of results for studies exploring prognostic relationships between ACB and quality of life (n=4) 
Scale/ Outcome Study 
 










ACBS≥1: 33% SF-36 PCS (Mean, 
SD): 49.0 (8.2) 
Multiple linear regression 
β (95% CI) 
NR -0.50 (-0.31, -0.68) 
p<.001 * 
EQ-5D       
(Range 0-1) 
Ie 201728 ACBS Mean (SD): 
0.55 (0.87) 
EQ-5D (Mean, SD): 
0.82 (0.14) 
Multiple linear regression 
β, SE (95% CI) 
NR 0.006, .009 (-0.01, 







ACBS≥1: 33% SF-36 PCS (Mean, 
SD): 49.0 (8.2) 
Multiple linear regression 
β (95% CI) 




Sura 201635 Ach user: 17 
(15.2%) 
NR Multiple linear regression 
Parameter estimate (95% CI) 








ACBS≥1: 33% SF-36 PCS (Mean, 
SD): 49.0 (8.2) 
Multiple linear regression 
β (95% CI) 








NR McGill QOL Mean 
(SD): 6.0 (2.0) 
Generalised linear models  
OR (95% CI) 






Ach: Anticholinergic, ACB: Anticholinergic Burden, ACBS: Anticholinergic Cognitive Burden Scale, ADS: Anticholinergic Drug Scale, ARS: Anticholinergic Risk 
Scale, DBI-Ach: Drug Burden Index Anticholinergic sub-scale, EQ-5D: EuroQol 5D, mCRAS: modified Clinician Rated Anticholinergic Score, MQoL: MacGill 
Quality of Life Score, nr: Not Reported, QoL: Quality of Life, SF-12 PCS: Short Form Health Survey 12 Physical Component, SF-36 PCS: Short Form Health Survey 
36 Physical Component. 
Adjustments: 
* Adjusted for age, sex, education, income, living alone, frailty, number of comorbidities, modified mini-mental state examination and Geriatric 
Depression Scale. 
† Adjusted for age, sex, living with someone, income, no. of comorbidities, use of assistive devices, falls < 12 months, baseline DBI ACH, baseline DBI-
SED, Baseline ACBS, no. regular medications, no. of BEERs list medications.   
‡ Adjusted for predisposing factors such as age, race/ethnicity, gender, marital status, and education. Enabling factors included family income, health 
insurance coverage, region, and metropolitan status area (MSA). Need factors comprised of perceived general and mental health status, activities of 
daily living (ADL), instrumental activities of daily living (IADL), and cholinesterase inhibitors. The baseline PCS and MCS summary scores were used as 
additional need factors. 





EQ-5D           
(Range 0-1) 
Ie 201528 DBI-Ach (Mean, 
SD): 0.05 (0.14) 
EQ-5D (Mean, SD): 
0.82 (0.14) 
Multiple linear regression 
Β, SE (95% CI) 
NR -0.09, .05 (-.19, 
.002) p<.05 b 
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